Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirsevimab in Japanese Infants With Health Conditions or Born Pre-Term
NCT06042049Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nirsevimab in respiratory syncytial virus infection (RSV), sponsored by AstraZeneca. Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs), and New-onset Chronic Diseases… Started Jul 2023; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06042049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06042049.